中国医药
(600056)
| 流通市值：163.59亿 | | | 总市值：163.65亿 |
| 流通股本：14.95亿 | | | 总股本：14.96亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 17,075,860,112.16 | 8,262,744,582.75 | 34,148,359,638.99 | 26,099,729,998.4 |
| 营业收入 | 17,075,860,112.16 | 8,262,744,582.75 | 34,148,359,638.99 | 26,099,729,998.4 |
| 二、营业总成本 | 16,438,279,511.82 | 7,973,445,487.28 | 32,983,445,215.42 | 25,216,783,611.99 |
| 营业成本 | 15,294,245,978.33 | 7,387,332,882.18 | 30,489,593,937.49 | 23,317,058,605.89 |
| 税金及附加 | 53,434,403.39 | 27,489,300.41 | 98,234,876.81 | 68,753,867.61 |
| 销售费用 | 494,676,658.69 | 242,630,292.96 | 1,099,225,919.18 | 836,164,693.31 |
| 管理费用 | 540,068,919.01 | 245,085,700.87 | 975,246,965.38 | 777,491,393.59 |
| 研发费用 | 65,629,033.38 | 33,518,271.97 | 125,219,820.99 | 89,752,947.32 |
| 财务费用 | -9,775,480.98 | 37,389,038.89 | 195,923,695.57 | 127,562,104.27 |
| 其中:利息费用 | 88,140,694.75 | 35,147,574.66 | 205,513,268.09 | 113,574,940.63 |
| 其中:利息收入 | 30,585,943.37 | 12,711,932.65 | 36,891,786.01 | 47,774,014.36 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 5,891,042.55 | 154,794.37 | 127,466,901.01 | -1,108,515.03 |
| 加:投资收益 | 9,456,884.26 | 7,559,129.15 | -65,016,832.54 | 5,002,730.82 |
| 资产处置收益 | 7,371,175.2 | -47,650.36 | 1,653,400.91 | 1,026,006.48 |
| 资产减值损失(新) | 265,715.11 | -2,069,741.33 | -175,325,505.38 | 1,150,416.96 |
| 信用减值损失(新) | -152,062,098.56 | 2,510,401.61 | -187,023,535.26 | -65,698,071.63 |
| 其他收益 | 16,366,929.96 | 7,244,850.21 | 64,899,006.22 | 27,245,720.58 |
| 四、营业利润 | 524,870,248.86 | 304,650,879.12 | 931,567,858.53 | 850,564,674.59 |
| 加:营业外收入 | 4,683,722.03 | 2,749,688.16 | 45,254,389.89 | 9,766,439.48 |
| 减:营业外支出 | 8,831,542.5 | 2,786,924.59 | 23,633,734.53 | 17,547,335.07 |
| 五、利润总额 | 520,722,428.39 | 304,613,642.69 | 953,188,513.89 | 842,783,779 |
| 减:所得税费用 | 145,395,307.93 | 77,413,614.06 | 266,564,631.87 | 221,865,802.33 |
| 六、净利润 | 375,327,120.46 | 227,200,028.63 | 686,623,882.02 | 620,917,976.67 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 375,327,120.46 | 227,200,028.63 | 686,623,882.02 | 620,917,976.67 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 293,959,402.72 | 166,379,236.02 | 535,467,687.81 | 447,148,326.32 |
| 少数股东损益 | 81,367,717.74 | 60,820,792.61 | 151,156,194.21 | 173,769,650.35 |
| 扣除非经常损益后的净利润 | 255,736,026.62 | 161,389,244.66 | 323,177,427.46 | 408,614,665.36 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.2 | 0.11 | 0.36 | 0.3 |
| (二)稀释每股收益 | 0.2 | 0.11 | 0.36 | 0.3 |
| 八、其他综合收益 | 2,628,805.36 | 884,977.29 | -362,481.48 | -3,545,260.38 |
| 归属于母公司股东的其他综合收益 | 2,628,805.36 | 884,977.29 | -383,971.37 | -3,545,260.38 |
| 九、综合收益总额 | 377,955,925.82 | 228,085,005.92 | 686,261,400.54 | 617,372,716.29 |
| 归属于母公司股东的综合收益总额 | 296,588,208.08 | 167,264,213.31 | 535,083,716.44 | 443,603,065.94 |
| 归属于少数股东的综合收益总额 | 81,367,717.74 | 60,820,792.61 | 151,177,684.1 | 173,769,650.35 |
| 公告日期 | 2025-08-28 | 2025-04-30 | 2025-04-26 | 2024-10-26 |
| 审计意见(境内) | | | 标准无保留意见 | |